Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06075485
Other study ID # 2023-A01073-42
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 15, 2024
Est. completion date June 2026

Study information

Verified date January 2024
Source Nutricia Nutrition Clinique
Contact Elmire DEGOUL-COMBESCOT, PhD
Phone +33 (0) 6 27 91 97 08
Email Elmire.DEGOUL@danone.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy. This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.


Description:

NUTRICIA has developed the KetoCal® range (4:1 and 3:1), a food for special medical purposes (DADFMS), to help healthcare professionals and patients establish and maintain a CR. KetoCal® 4:1 features a 4:1 ratio of fat to (carbohydrate + protein), while containing vitamins, minerals, trace elements and fiber. Similarly, KetoCal® 3:1 has a 3:1 ratio of lipids / (carbohydrates + proteins), while containing vitamins, minerals, trace elements and fiber. The KetoCal® range can be consumed orally, as a drink after dilution in hot water, incorporated as an ingredient in a recipe or administered by enteral feeding tube. The KEOPS study is designed to gather real-life data on the therapeutic value of using the KetoCal® range in the management of drug-resistant epilepsy in infants (from 5 months) and children up to 18 years of age. Patients will be managed according to standard care practices. Initiation of ketogenic dieting will be at the investigator's discretion during the child's hospitalization.


Recruitment information / eligibility

Status Recruiting
Enrollment 133
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 5 Months to 18 Years
Eligibility Inclusion Criteria: - Infants from 5 months and children up to 17 years of age (maximum 18 years minus 1 day). - With drug-resistant epilepsy according to ILAE (International League Against Epilepsy) criteria: persistence of epileptic seizures after failure of two appropriate antiepileptic drugs tried consecutively or in well-tolerated combination. - Indication for CR by a physician. - Parents (or legal guardians) able to set up and follow the diet, assessed during a joint doctor-dietician consultation. - Written authorization from one (or both) parents or the child's legal representative to collect personal information about their child. - Affiliation of the infant/child with the social security system. Exclusion Criteria: - Contraindication to ketogenic diet at initial assessment. - Children already on a ketogenic diet. - Parenteral nutrition. - Concurrent prescription of other foodstuffs intended for special medical purposes (DADFMS) such as KetoVie or Keyo. - Protected legal representative (under legal protection, or deprived of liberty by judicial or administrative decision). - Legal representative not covered by a social security scheme. - Legal representative unable to understand study protocol. Ancillary study eligibility criteria : - Patients included in the study. - Continued on the ketogenic diet for at least 2 months. - Having consented to participate in the ancillary study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ketocal
ketogene diet

Locations

Country Name City State
France CHRU Lille Lille

Sponsors (2)

Lead Sponsor Collaborator
Nutricia Nutrition Clinique Euraxi Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Description of compliance Retention rate which is defined as the proportion of patients who have continued KD for up to 6 months. 6 months
Secondary Duration of compliance Describe the duration of KD compliance. From Month 1 to Month 6
Secondary Efficacy of KD Describe the efficacy of KD. Efficacy is defined as responders to KD with seizure frequency reduced by more than 50%, or no seizure frequency in the case of total response to CR in the last week. From Month 1 to Month 6
Secondary KD tolerance. Describe KD tolerance as a number of AE reported From inclusion to Month 6
Secondary QoL evolution Describe changes in patients' quality of life following initiation of KD at inclusion, and M6; using PedsQL ™ questionnaires From inclusion to Month 6
Secondary Influence of KD Total number of antiepileptic drugs used for each child including their current treatment until the end of the study. From inclusion to Month 6
Secondary Ketosis achievement Evaluate the time it takes to achieve ketosis. Ketosis will be assessed by ketonuria or ketonemia, depending on the habits of each center. From inclusion to Month 6
See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05928598 - Goals for Epilepsy Clinic Visits Trial N/A
Recruiting NCT05539287 - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Phase 2
Not yet recruiting NCT04601974 - Lentiviral Gene Therapy for Epilepsy Phase 1/Phase 2
Completed NCT02982824 - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy N/A
Recruiting NCT05485558 - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy Phase 2
Not yet recruiting NCT04553354 - Cortical Resections in Drug Resistant Epilepsy
Recruiting NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy N/A
Recruiting NCT04714996 - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy Phase 2
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Recruiting NCT06059157 - Epileptogenic Network Visualisation With Advanced MRI N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Recruiting NCT05393518 - Electroclinical Correlation of Anxiety N/A
Not yet recruiting NCT05555537 - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed NCT03419000 - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY N/A
Enrolling by invitation NCT06341075 - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy N/A
Not yet recruiting NCT05527093 - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy N/A
Recruiting NCT05697614 - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children Phase 4
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT06432907 - StereoEEG Motor Neuronal Potentials Decoding N/A